GlassScriptPhysician profile
Frank W Smart
NPI 1275571341
$4,294.71
in general payments reported to CMS, 2019-2025
29 companies · $767 in 2025
The $767 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $526 · 2021: $479 · 2022: $464 · 2023: $333 · 2024: $867 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Education: $96.81 · Travel and Lodging: $58.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.59 |
| Education | $96.81 |
| Travel and Lodging | $58.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $790.85 | 2019-2025 | Cardiomems |
| Abiomed | $427.53 | 2019-2025 | |
| Pfizer INC. | $375.79 | 2019-2025 | |
| Amgen INC. | $293.05 | 2019-2023 | Repatha |
| Eli Lilly and Company | $291.05 | 2024 | |
| Recor Medical INC | $267.01 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $239.37 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Evoque |
| Impulse Dynamics (USA) INC. | $181.58 | 2021-2022 | |
| Medtronic Vascular, INC. | $145.75 | 2020 | |
| Novo Nordisk INC | $137.91 | 2023-2024 | Rybelsus, Ozempic |
| Angiodynamics, INC. | $137.87 | 2025 | Alphavac, Auryon Laser System 100-120 Vac |
| Philips North America LLC | $132.25 | 2019-2023 | |
| Penumbra, INC. | $124.99 | 2025 | Indigo System |
| Mallinckrodt Enterprises LLC | $115.72 | 2019 | |
| Janssen Scientific Affairs, LLC | $113.71 | 2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $101.32 | 2022-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $94.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $77.88 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.61 | 2022-2023 | Jardiance |
| Amryt Pharma Holdings LTD | $39.91 | 2020-2022 | |
| Aegerion Pharmaceuticals, INC. | $29.93 | 2019 | |
| Convatec INC. | $27.29 | 2019 | |
| Kestra Medical Technology Services, INC. | $19.00 | 2022 | |
| Esperion Therapeutics, INC. | $17.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.15 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.19 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.